Studies with dasatinib for de novo Philadelphia chromosome–positive (Ph+) ALL.
| Reference . | N (evaluated) . | Age. y (range) . | Dasatinib, mg/d . | ChThx regimen . | Schedule of TKI and ChThx . | CR,% . | PCR negative,% . | Induction death, n (%) . | Relapse, n (%) . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|
| *22 patients with de novo Ph+ALL, 6 pts. with one prior treatment cycle | ||||||||||
| OS indicates overall survival; CR, complete remission; ChThx, chemotherapy; hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; IND, induction; na, not applicable; EWALL: European Working Group for Adult ALL of the European LeukemiaNet | ||||||||||
| Ravandi F 2008 18 | 28* | 52 (21–79) | 100 QD | HyperCVAD | D1–14 of each cycle | 93 | 50 | 2 (7) | 5 (18) | CR (10 mo): 18 (64%) OS (10 mo): 21 (75%) |
| Rousselot P 2008 19 | 22 | 71 (61–83) | 140 QD 100 QD | EWALL elderly | IND: parallel, then alternating | 95 | 28 | 1 (4.5) | 1 (4.5) | na |
| Foa R 2008 20 | 48 (34) | 54 (24–76) | 70 BID | Steroid prephase, then 12 wk dasatinib | Post-induction therapy not defined | 100 | na | 0 | 9 (27) | OS (10 mo): 81% |
| Reference . | N (evaluated) . | Age. y (range) . | Dasatinib, mg/d . | ChThx regimen . | Schedule of TKI and ChThx . | CR,% . | PCR negative,% . | Induction death, n (%) . | Relapse, n (%) . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|
| *22 patients with de novo Ph+ALL, 6 pts. with one prior treatment cycle | ||||||||||
| OS indicates overall survival; CR, complete remission; ChThx, chemotherapy; hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; IND, induction; na, not applicable; EWALL: European Working Group for Adult ALL of the European LeukemiaNet | ||||||||||
| Ravandi F 2008 18 | 28* | 52 (21–79) | 100 QD | HyperCVAD | D1–14 of each cycle | 93 | 50 | 2 (7) | 5 (18) | CR (10 mo): 18 (64%) OS (10 mo): 21 (75%) |
| Rousselot P 2008 19 | 22 | 71 (61–83) | 140 QD 100 QD | EWALL elderly | IND: parallel, then alternating | 95 | 28 | 1 (4.5) | 1 (4.5) | na |
| Foa R 2008 20 | 48 (34) | 54 (24–76) | 70 BID | Steroid prephase, then 12 wk dasatinib | Post-induction therapy not defined | 100 | na | 0 | 9 (27) | OS (10 mo): 81% |